SEC Form 4	ŀ
------------	---

П

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB AP	PROVAL
/IB Number:	3235-02

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

STATEMENT	OF (CHANGES	IN BE	NEFICIAL	OWNERS	HIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			2. Issuer Name and Ticker or Trading Symbol <u>Oncology Institute, Inc.</u> [TOI]							lationship k all app Direc				Issuer Owner					
(Last) 2100 MC	•	rst) (I AVE, SUITE 17	Viddle) 60		3. Date of Earliest Transaction (Month/Day/Year) 10/18/2022					Office below	er (give title /)	e	Othe below	r (specify v)					
(Street) DALLAS	5 ТУ	ζ 7	5201		4. If Amendm									6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting					
(City)	(St	ate) (2	Zip)												Perso	n			
		Table	l - No	on-Deriva	tive S	Sec	urities	s Acc	quirec	l, Dis	sposed of	, or B	Benefi	ciall	y Own	ed			
1. Title of S	Security (Ins	tr. 3)		2. Transacti Date (Month/Day	/Year) If any		ny	cution Date,		action Instr.	4. Securities Disposed Of 5)	f (D) (Ins	str. 3, 4 a	4 and Securities Beneficially Owned Follow Reported		es ally ⁼ollowing d	y (D) or Indir lowing (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
										v	Amount	(A) or (D)	Price	,	Transac (Instr. 3				
Common	stock			10/18/20)22				S		12,200	D	\$4.6	53 ⁽¹⁾	14,41	0,860		Ι	See footnote ⁽⁴⁾
Common	stock			10/19/20)22				S		17,500	D	\$4.6	58 ⁽²⁾	14,39	93,360		I	See footnote ⁽⁴⁾
Common	stock			10/20/20)22				S		12,000	D	\$4.8	3 ³⁽³⁾	14,38	31,360		I	See footnote ⁽⁴⁾
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, Tr urity or Exercise (Month/Dav/Year) if any Co		Transaction of Code (Instr. Derivative		Expiration Date (Month/Day/Year) s			Amount of Securities Underlying Derivative Security (In: 3 and 4)						10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)				
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amoun or Numbe of Shares	r					
		Reporting Person*	T	D															
Havencrest Healthcare Partners, L.P.																			
(Last) 2100 MC		(First) AVE, SUITE 17		iddle)															
(Street) DALLAS	5	TX	75	5201															
(City)		(State)	(Zi	p)		-													
		Reporting Person*		<u>P, LLC</u>															
(Last) 2100 MC		(First) AVE, SUITE 17		iddle)		_													
(Street) DALLAS	8	TX	75	201															
(City)		(State)	(Zi	p)		_													
	nd Address of <u>CI, LLC</u>	Reporting Person*																	

(Last) 2100 MCKINN	(First) EY AVE, SUITE	(Middle)
(Street) DALLAS	ТХ	75201
(City)	(State)	(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.44 to \$4.92, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.45 to \$4.82, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.51 to \$5.12, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

4. TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

Remarks:

<u>/s/ Havencrest Healthcare</u> <u>Partners, L.P., by Kyle Seco,</u> <u>as attorney-in-fact</u>	<u>10/20/2022</u>
/s/ Havencrest Healthcare Partners GP, LLC, by Kyle Seco, as attorney-in-fact	<u>10/20/2022</u>
/s/ TOI HC I, LLC, by Kyle Seco, as attorney-in-fact	10/20/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.